SIRs and AERs of subsequent BC incidence in males
| Characteristic . | No. of patients (%) . | Male BC cases . | SIR (95% CI) . | AER (95% CI) . |
|---|---|---|---|---|
| Overall | 3077 (100) | 8 | 23.3 (10.1-46.0) | 1.6 (0.7-3.3) |
| Age at HL diagnosis, y | ||||
| <25 | 1036 (33.7) | 3 | 69.0 (14.2-201.6) | 1.6 (0.3-4.9) |
| 25-34 | 1022 (33.2) | 4 | 43.5 (11.8-111.3) | 2.5 (0.6-6.4) |
| 35-50 | 1019 (33.1) | 1 | 4.8 (0.1-26.9) | 0.6 (−0.1 to 4.1) |
| Treatment period | ||||
| 1965-1979 | 623 (20.3) | 2 | 20.6 (2.5-74.4) | 1.5 (0.1-5.8) |
| 1980-1995 | 1325 (43.1) | 5 | 31.2 (10.1-72.9) | 2.2 (0.7-5.3) |
| 1996-2013 | 1129 (36.7) | 1 | 11.7 (0.3-65.2) | 0.7 (−0.05 to 4.2) |
| Follow-up after HL treatment/interval HL treatment and male BC, y | ||||
| 5-9 | 431 (14.0) | 0 | — | — |
| 10-19 | 1120 (36.4) | 2 | 14.6 (1.8-52.9) | 0.9 (0.04-3.3) |
| 20-29 | 1094 (35.6) | 5 | 42.1 (13.7-98.3) | 5.3 (1.6-12.4) |
| ≥30 | 432 (14.0) | 1 | 23.1 (0.6-128.6) | 4.8 (−0.1 to 27.5) |
| Attained age at end of follow-up, y | ||||
| <40 | 567 (18.4) | 1 | 54.8 (1.4-305.6) | 0.6 (0.004-3.2) |
| 40-49 | 878 (28.5) | 1 | 18.4 (0.5-102.6) | 0.6 (−0.02 to 3.7) |
| 50-59 | 938 (30.5) | 5 | 40.4 (13.1-94.3) | 4.6 (1.4-10.9) |
| ≥60 | 694 (22.3) | 1 | 6.8 (0.2-38.1) | 2.0 (−0.3 to 12.8) |
| HL treatment | ||||
| RT alone | 683 (22.2) | 1 | 10.1 (0.3-56.1) | 0.7 (−0.1 to 4.4) |
| CT alone | 402 (13.1) | 0 | — | — |
| RT + CT | 1992 (64.7) | 7 | 35.3 (14.2-72.8) | 2.3 (0.9-4.9) |
| HL treatment according to chest RT∗,and alkylating CT† | ||||
| Chest RT (with or without other RT fields) only | 549 (17.8) | 1 | 12.7 (0.3-70.6) | 0.9 (−0.1 to 5.4) |
| Chest RT (with or without other RT fields) and nonalkylating CT | 151 (4.9) | 1 | 56.5 (1.4-315.0) | 3.4 (0.03-19.1) |
| Chest RT (with or without other RT fields) and alkylating CT | 1352 (43.9) | 5 | 41.1 (13.4-96.0) | 2.5 (0.8-6.0) |
| Other RT fields and alkylating CT | 433 (14.1) | 1 | 19.0 (0.5-106.1) | 1.6 (−.0.4 to 9.1) |
| Other RT fields with or without nonalkylating CT | 190 (6.2) | 0 | — | — |
| CT only‡ | 402 (13.1) | 0 | — | — |
| HL treatment according to chest RT∗ and anthracycline-containing CT | ||||
| Chest RT (with or without other RT fields) only | 549 (17.8) | 1 | 12.7 (0.3-70.6) | 0.9 (−0.1-5.4) |
| Chest RT (with or without other RT fields) and no anthracycline-containing CT | 471 (15.3) | 2 | 35.7 (4.3-128.9) | 2.4 (0.2-8.7) |
| Chest RT (with or without other RT fields) and anthracycline-containing CT | 1032 (33.5) | 4 | 48.1 (13.1-123.1) | 2.8 (0.7-7.3) |
| Other RT fields and anthracycline-containing CT | 390 (12.7) | 0 | — | — |
| Other RT fields with or without no anthracycline-containing CT | 233 (7.6) | 1 | 28.4 (0.7-158.2) | 2.3 (−0.02 to 13.1) |
| CT only‡ | 402 (13.1) | 0 | — | — |
| Characteristic . | No. of patients (%) . | Male BC cases . | SIR (95% CI) . | AER (95% CI) . |
|---|---|---|---|---|
| Overall | 3077 (100) | 8 | 23.3 (10.1-46.0) | 1.6 (0.7-3.3) |
| Age at HL diagnosis, y | ||||
| <25 | 1036 (33.7) | 3 | 69.0 (14.2-201.6) | 1.6 (0.3-4.9) |
| 25-34 | 1022 (33.2) | 4 | 43.5 (11.8-111.3) | 2.5 (0.6-6.4) |
| 35-50 | 1019 (33.1) | 1 | 4.8 (0.1-26.9) | 0.6 (−0.1 to 4.1) |
| Treatment period | ||||
| 1965-1979 | 623 (20.3) | 2 | 20.6 (2.5-74.4) | 1.5 (0.1-5.8) |
| 1980-1995 | 1325 (43.1) | 5 | 31.2 (10.1-72.9) | 2.2 (0.7-5.3) |
| 1996-2013 | 1129 (36.7) | 1 | 11.7 (0.3-65.2) | 0.7 (−0.05 to 4.2) |
| Follow-up after HL treatment/interval HL treatment and male BC, y | ||||
| 5-9 | 431 (14.0) | 0 | — | — |
| 10-19 | 1120 (36.4) | 2 | 14.6 (1.8-52.9) | 0.9 (0.04-3.3) |
| 20-29 | 1094 (35.6) | 5 | 42.1 (13.7-98.3) | 5.3 (1.6-12.4) |
| ≥30 | 432 (14.0) | 1 | 23.1 (0.6-128.6) | 4.8 (−0.1 to 27.5) |
| Attained age at end of follow-up, y | ||||
| <40 | 567 (18.4) | 1 | 54.8 (1.4-305.6) | 0.6 (0.004-3.2) |
| 40-49 | 878 (28.5) | 1 | 18.4 (0.5-102.6) | 0.6 (−0.02 to 3.7) |
| 50-59 | 938 (30.5) | 5 | 40.4 (13.1-94.3) | 4.6 (1.4-10.9) |
| ≥60 | 694 (22.3) | 1 | 6.8 (0.2-38.1) | 2.0 (−0.3 to 12.8) |
| HL treatment | ||||
| RT alone | 683 (22.2) | 1 | 10.1 (0.3-56.1) | 0.7 (−0.1 to 4.4) |
| CT alone | 402 (13.1) | 0 | — | — |
| RT + CT | 1992 (64.7) | 7 | 35.3 (14.2-72.8) | 2.3 (0.9-4.9) |
| HL treatment according to chest RT∗,and alkylating CT† | ||||
| Chest RT (with or without other RT fields) only | 549 (17.8) | 1 | 12.7 (0.3-70.6) | 0.9 (−0.1 to 5.4) |
| Chest RT (with or without other RT fields) and nonalkylating CT | 151 (4.9) | 1 | 56.5 (1.4-315.0) | 3.4 (0.03-19.1) |
| Chest RT (with or without other RT fields) and alkylating CT | 1352 (43.9) | 5 | 41.1 (13.4-96.0) | 2.5 (0.8-6.0) |
| Other RT fields and alkylating CT | 433 (14.1) | 1 | 19.0 (0.5-106.1) | 1.6 (−.0.4 to 9.1) |
| Other RT fields with or without nonalkylating CT | 190 (6.2) | 0 | — | — |
| CT only‡ | 402 (13.1) | 0 | — | — |
| HL treatment according to chest RT∗ and anthracycline-containing CT | ||||
| Chest RT (with or without other RT fields) only | 549 (17.8) | 1 | 12.7 (0.3-70.6) | 0.9 (−0.1-5.4) |
| Chest RT (with or without other RT fields) and no anthracycline-containing CT | 471 (15.3) | 2 | 35.7 (4.3-128.9) | 2.4 (0.2-8.7) |
| Chest RT (with or without other RT fields) and anthracycline-containing CT | 1032 (33.5) | 4 | 48.1 (13.1-123.1) | 2.8 (0.7-7.3) |
| Other RT fields and anthracycline-containing CT | 390 (12.7) | 0 | — | — |
| Other RT fields with or without no anthracycline-containing CT | 233 (7.6) | 1 | 28.4 (0.7-158.2) | 2.3 (−0.02 to 13.1) |
| CT only‡ | 402 (13.1) | 0 | — | — |
Bold numbers indicate statistically significant SIRs and AERs (P < .05).
CT, chemotherapy; MOPP, mechlorethamine, vincristine, procarbazine, and prednisone; RT, radiotherapy.
Chest radiotherapy was defined as mantle field RT or RT to the mediastinum, lungs, or axilla.
Alkylating chemotherapy consists of combinations of cytostatic agents with at least 1 alkylating agent (ie, procarbazine, cyclophosphamide, ifosfamide, lomustine, melphalan, dacarbazine, cisplatin, mechlorethamine, chlorambucil, or carmustine).
CT-only category includes patients who have been treated with chemotherapy only, mainly including doxorubicin, bleomycin, vinblastine, and dacarbazine, or MOPP, doxorubicin, bleomycin, and vinblastine.